Treatment News : Genetically Modifying Cells to Resist HIV Shows Promise

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 5, 2014

Genetically Modifying Cells to Resist HIV Shows Promise

CROI 2014A technique for genetically modifying the immune cells of people with HIV to resist the virus has shown promise in an early safety trial, raising the hope that such treatment may one day offer an alternative to daily antiretroviral (ARV) therapy, The New York Times reports. Publishing their findings in The New England Journal of Medicine, investigators used Sangamo BioSciences’ zinc-finger nucleases (ZFNs) technology to manipulate CD4 cell genes.

Researchers drew CD4 cells from 12 HIV-positive participants on stable ARVs and used the ZFN tool to edit the cells’ genetic code for the CCR5 receptor so as to resist the virus. Most variants of HIV must use the CCR5 receptor in order to enter the cell. The investigators then prompted the cells to multiply and eventually infused each participant with 10 billion of their own CD4 cells, about a fifth of which had a mutated CCR5 gene.

After four weeks, six of the participants stopped taking their ARVs in a planned treatment interruption that was intended to last 12 weeks. All of their viral loads were undetectable at the beginning of the treatment interruption and eventually became detectable before they returned to HIV therapy. Two began ARVs again eight weeks into the interruption because of rapidly rising viral loads.

On average, the peak viral loads of the four participants who completed the full 12-week interruption were more than 90 percent lower than their pre-ARV peak levels. In one of the participants, who the investigators discovered already had the beneficial CCR5 mutation in half of his or her genes, the viral load peaked at 6,247 at week six, after which it declined to an undetectable level.

Investigators concluded that the treatment was generally safe and that the modified CD4s appeared to be resistant to HIV.

To read the National Institutes of Health press release, click here.

To read the Times story, click here.

Search: ZFN, zinc-finger nucleases, Sangamo BioSciences, New England Journal of Medicine, CCR5 mutation.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.